Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the 2021 BioConnect Virtual Conference hosted by H.C. Wainwright. Registered attendees can access the recorded presentation on-demand (24x7) for the duration of the conference.
|Conference Date:||January 11-14, 2021 (Monday-Thursday)|
|On-Demand Starts:||6:00am ET - Monday, January 11, 2021|
|On-Demand Ends||9:00pm ET- Thursday, January 14, 2021|
Mr. Roberts will highlight the Company’s recent transformational business strategy, discuss near-term events including the Company’s proposed merger with StemoniX, Inc., and the broader corporate vision of the Company going forward.
CGIX will be available for virtual 1:1 meetings both during and after the BioConnect Conference. Please contact Jennifer K. Zimmons, Ph.D. firstname.lastname@example.org 917.214.3514 for scheduling.
ABOUT CANCER GENETICS
Through its vivo Pharm subsidiary, Cancer Genetics offers proprietary preclinical test systems supporting drug discovery programs, valued by the pharmaceutical industry, biotechnology companies and academic research centers. The Company is focused on precision and translational medicine to drive drug discovery and novel therapies. vivo Pharm specializes in conducting studies tailored to guide therapeutic development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivo Pharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. For more information, please visit www.cancergenetics.com.
For more information, please visit or follow CGI at:
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our ability to satisfy all closing conditions to the merger with StemoniX, Inc. and realize the expected benefits therefrom, our attempts to adapt to the global coronavirus pandemic, our attempts to achieve profitability by increasing sales of our pre-clinical services, maintain our existing customer base and avoid cancellation of customer contracts or discontinuance of trials, our attempts to raise capital to meet our liquidity needs, market and other conditions, and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2019 and Form 10-Q for the quarter ended June 30, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Jennifer K. Zimmons. Ph.D.
Zimmons International Communications, Inc.